Archimedes, the Greek mathematician and physicist once said, “Give me a lever long enough and a fulcrum on which to place it, ...

I made a template of the arms and legs from heavy paper and traced it onto the wood. (Photo courtesy of Jess Mancini) My dad about 65 years ago made a toy for my little brother and me that amazed us.

Fulcrum Therapeutics (FULC) on Saturday reported positive initial results from the ongoing 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease. “We are highly ...

LEVER & FULCRUM SOLUTIONS PRIVATE LIMITED is a Private Limited Company, governed by the Companies Act as a company limited by shares. Classified as a Non-government company, it is registered under the ...

CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

Henry’s Lever Action Supreme is built on a brand-new action that seems like a cross between their Long Ranger rifle and an AR15. Like the Long Ranger rifle, the Lever Action Supreme’s action is ...

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to ...

Fulcrum says its new Soniq 42 wheels “maximise comfort” thanks to their FF80 carbon lamination rims, while the sawtooth rim profile optimises aerodynamics and stability. These features are a ...

Mindshare Fulcrum, the specialised media agency under WPP Media (formerly GroupM), has announced the appointment of Kosal Malladi as its new Digital Head. The move reflects the agency’s continued ...

Fulcrum Therapeutics (NASDAQ:FULC) fell ~10% on Tuesday after the company posted data from a late-stage study of its lead candidate, Pociredir, in sickle cell disease, along with second quarter ...